Trending tech news
Health and Wellness
Food And Drinks
Aimmune is a clinical-stage biopharmaceutical company. Our mission is to improve the lives of people with food allergies. Guidelines on our site
Companies in the same industry
Ready, Set, Food!
Home Team Therapy
Alexa global traffic share
Terms of Service
Plans & Pricing
by Datalicious ©2021
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.
Post-IPO equity - 2016
Nestlé Health Science
I work here
Explore United States
Nestlé to Swallow Up Peanut Allergy Drug Maker Aimmune in $2.6B Deal
Reuters Top News
Nestle pays $2 billion to secure Aimmune's allergy treatment
Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing
Bio Roundup: POTUS on Prices, a16z's Fund, Aimmune's Approval & More
Aimmune Gets $200M From Nestlé; Licenses Food Allergy Drug Candidate
FDA approves Aimmune's peanut allergy drug
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
Advisory Body Backs Aimmune Peanut Allergy Drug, Next Up: the FDA
FDA focuses on safety in review of Aimmune's peanut allergy drug
DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead
FDA's Gottlieb Adds Confusion to Aimmune's Claims of Shutdown Delay
Government Shutdown Hits Biotech as FDA Punts Review of Aimmune Drug
Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment...
Aimmune Prices Upsized $160M IPO, Climbs Higher in Debut
Aimmune May Seek Up To $115M in IPO for Allergy Therapy Drug